Last reviewed · How we verify

loratadine; montelukast

Organon and Co · Phase 3 active Small molecule

Loratadine is an antihistamine that blocks the action of histamine, a substance in the body that causes allergy symptoms, while montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, substances in the body that cause inflammation and constriction of airways.

Loratadine is an antihistamine that blocks the action of histamine, a substance in the body that causes allergy symptoms, while montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, substances in the body that cause inflammation and constriction of airways. Used for Perennial allergic rhinitis, Chronic idiopathic urticaria, Asthma.

At a glance

Generic nameloratadine; montelukast
SponsorOrganon and Co
Drug classHistamine H1 antagonist, Leukotriene receptor antagonist
TargetH1 receptor, CysLT1 receptor
ModalitySmall molecule
Therapeutic areaAllergy, Asthma
PhasePhase 3

Mechanism of action

Loratadine works by selectively inhibiting peripheral H1 receptors, which are responsible for the symptoms of allergies, such as itching, sneezing, and runny nose. Montelukast, on the other hand, works by blocking the action of cysteinyl leukotrienes, which are involved in the inflammatory response and airway constriction associated with asthma and allergies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: